Rigel Pharmaceuticals(FRA) RI2A

Market CapN/A

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

N/A

Rigel Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$237.37

Net Income (TTM)

$276.45

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

RI2A News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Industry

Biotechnology

Sector

Health Care

Employees

174

CEO

Raul R. Rodriguez, MBA

Website

www.rigel.com

RI2A Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Rigel Pharmaceuticals Performance Analysis

Rigel Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 114,410,027	-9.4%
2023	2023-12-31	USD 108,112,398	-5.5%
2024	2024-12-31	USD 165,738,682	53.3%
2025	2025-12-31	USD 260,754,696	57.3%

Rigel Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.23	263.7%
2023	2023-12-31	USD -1.33	-58.7%
2024	2024-12-31	USD 0.91	N/A
2025	2025-12-31	USD 17.26	1788.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$67.69

+0.8%

Gross Profit

$60.36

+0.7%

Gross Margin

89.17%

+0.9%

Market Cap

N/A

Market Cap/Employee

$3.57

N/A

Employees

174

N/A

Net Income

$14.87

+0.3%

EBITDA

$21.01

+0.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$88.14

-9.6%

Total Debt

$34.94

+0.7%

Accounts Receivable

$49.02

+1.4%

Inventory

$12.57

+1.4%

Long Term Debt

$0.05

+0.0%

Short Term Debt

$34.89

+1.8%

Return on Assets

87.50%

+1.5%

Return on Invested Capital

-47.63%

N/A

Free Cash Flow

$26.38

+1.0%

Operating Cash Flow

$26.38

+1.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About RI2A

What is the current price of Rigel Pharmaceuticals?

Rigel Pharmaceuticals is trading at N/A per share.

What is the 52-week range for Rigel Pharmaceuticals?

Over the past 52 weeks, Rigel Pharmaceuticals has traded between N/A and N/A.

How much debt does Rigel Pharmaceuticals have?

As of the most recent reporting period, Rigel Pharmaceuticals reported total debt of $34.94M.

How much cash does Rigel Pharmaceuticals have on hand?

Rigel Pharmaceuticals reported $53.19M in cash and cash equivalents in its most recent financial results.

What is Rigel Pharmaceuticals’s dividend yield?

Rigel Pharmaceuticals does not currently have a dividend yield.

Rigel Pharmaceuticals(FRA) RI2A

Rigel Pharmaceuticals Financials at a Glance

RI2A News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Rigel Pharmaceuticals

RI2A Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Rigel Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RI2A

What is the current price of Rigel Pharmaceuticals?

What is the 52-week range for Rigel Pharmaceuticals?

How much debt does Rigel Pharmaceuticals have?

How much cash does Rigel Pharmaceuticals have on hand?

What is Rigel Pharmaceuticals’s dividend yield?

Premium Investing Services